Clinical Trials

Third International Stroke Trial

2012-05-23 23:11:00

The goal of the trial was to evaluate treatment with intravenous thrombolytic therapy compared with control among a broad range of patients presenting within 6 hours from onset of ischemic stroke.

Aspirin for the Prevention of Recurrent Venous Thromboembolism (Warfarin and Aspirin)

2012-05-23 12:34:00

The goal of the trial was to evaluate treatment with aspirin compared with placebo among patients with treated venous thromboembolism.

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction

2012-05-14 12:27:00

Chronic systolic heart failure (CHF) is associated with a hypercoagulable state. Earlier trials on the use of warfarin in patients with CHF had included patients with atrial fibrillation (AF) and valvular heart disease, and thus, the true value of anticoagulation in patients with CHF but no other obvious cause for anticoagulation is unknown. Accordingly, the WARCEF trial sought to compare outcomes between the use of warfarin and aspirin in patients with CHF and normal sinus rhythm (NSR).

Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing

2012-05-12 14:31:00

Warfarin is a commonly prescribed medication that has a narrow therapeutic range, with marked interpatient variability in PK and PD. Pharmacogenetic (PG) studies have identified two genes, CYP2C9 (cytochrome p450 isoform) and VKORC1 (vitamin K epoxide reductase complex subunit 1), to consistently determine warfarin dose requirements. However, studies incorporating genotype analysis and tailored therapy have been inconsistent. The current trial sought to study the safety and efficacy of two PG algorithms on the ability to achieve therapeutic anticoagulation with warfarin.

Testing platelet Reactivity In patients underGoing elective stent placement on clopidogrel to Guide alternative thErapy with pRasugrel

2012-04-18 16:45:00

The TRIGGER-PCI trial sought to study whether treatment with prasugrel in nonresponders to clopidogrel would be associated with an improvement in platelet reactivity testing on follow-up.

PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY

2012-04-10 14:05:00

Current guidelines recommend that dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine be continued for a minimum of 12 months following drug-eluting stent (DES) percutaneous coronary intervention (PCI). This recommendation comes from data from numerous observational studies suggesting that early DAPT discontinuation is associated with an increased risk of stent thrombosis. However, randomized controlled data to support this recommendation are lacking. Accordingly, the PRODIGY investigators sought to study if 24 months of DAPT is superior to 6 months of DAPT in all-comers undergoing PCI with both DES and bare-metal stents (BMS).

Randomized Trial of Tenecteplase Versus Alteplase for Acute Ischemic Stroke

2012-04-10 13:53:00

Current guidelines recommend that intravenous alteplase (tPA) be administered for systemic fibrinolysis in patients presenting with acute ischemic stroke within 3 hours (Grade I) and within 4.5 hours (Grade IIC) of onset of symptoms. Tenecteplase (TNK) is a genetically modified version of tPA that has some pharmacokinetic benefits over tPA. The current phase II trial sought to compare outcomes in patients with acute ischemic stroke randomized to receive two low doses of TNK versus standard dose of tPA.

Clopidogrel for High Atherothrombotic Risk, Ischemic Stabilization, Management, and Avoidance

2012-04-05 17:00:00

The goal of the trial was to evaluate antiplatelet treatment with aspirin alone compared with aspirin plus clopidogrel among high-risk patients with stable cardiovascular (CV) disease.

Reassessment of Anti-Platelet Therapy Using an Individualized Strategy Based on Genetic Evaluation

2012-04-03 21:38:00

The goal of the trial was to evaluate a strategy of rapid genotyping for the CYP2C19*2 allele with selective use of prasugrel (in carriers of the CYP2C19*2 allele) compared with standard therapy with clopidogrel (in noncarriers of the CYP2C19*2 allele) among patients undergoing percutaneous coronary intervention (PCI).

Moderate Pulmonary Embolism Treated With Thrombolysis

2012-03-27 00:57:00

The goal of the trial was to evaluate treatment with low-dose thrombolytic therapy compared with usual care among patients with hemodynamically stable moderate pulmonary embolism (PE).

Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care

2012-03-27 00:44:00

The goal of the trial was to evaluate treatment with intravenous glucose, insulin, and potassium (GIK) compared with placebo when given early during a suspected acute coronary syndrome (ACS).

Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography

2012-03-27 00:35:00

The goal of the trial was to evaluate a strategy of cardiac computed tomography (CT) angiography compared with standard emergency department (ED) evaluation among patients with suspected acute coronary syndrome (ACS).

EINSTEIN–Pulmonary Embolism (PE) Study

2012-03-26 15:33:00

The goal of the trial was to evaluate treatment of the oral direct factor Xa inhibitor, rivaroxaban, compared with standard therapy among patients with symptomatic pulmonary embolism (PE).

CT Angiography for Safe Discharge of Patients With Possible Acute Coronary Syndromes

2012-03-26 14:46:00

The goal of the trial was to evaluate a strategy of cardiac computed tomography (CT) angiography compared with traditional care among low- to intermediate-risk patients with possible acute coronary syndrome (ACS).

CABG Off or On Pump Revascularization Study

2012-03-26 13:38:00

The goal of the trial was to evaluate off-pump compared with on-pump technique among patients undergoing coronary artery bypass grafting (CABG).